Convulsant activity and pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of gemifloxacin in rats

Journal of Pharmaceutical Sciences

Volumn 99, Issue 3, 2010, Pages 1535-1547

  Roy, Bikash ^a   Bose, Anirbandeep ^a   Bhaumik, Uttam ^a   Das, Ayan ^a   Chatterjee, Nilendra ^a   Ghosh, Animesh ^a   Darbar, Soumendra ^a   Sarkar, Amlan Kanti ^a   Sengupta, Pinaki ^a   Pal, T K ^a  

^a JADAVPUR UNIVERSITY   (India)

Author keywords

In vitro models; Pharmacodynamics; Pharmacokinetic pharmacodynamic models; Pharmacokinetics; UV Visible spectroscopy

Indexed keywords

GEMIFLOXACIN;

ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFECT; ELECTROENCEPHALOGRAM; FEMALE; FOCAL EPILEPSY; MALE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RAT; TREMOR;

EID: 76649115878     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21888     Document Type: Article

References (49)

1. Hussy P, Maass G, Tmmler B, Grosse F, Schomburg U. 1986. Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase a primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts. Antimicrob Agents Chemother 29:1073-1108.
2. Gootz TD, Barret JF, Holden HE, Ray VA, Mcguirk PR. 1990. Selective toxicity: The activity of 4-quinolones against eukaryotic DNA topoisomerase. In: Crumplin G, editor. 4-Quinolones: Antibacterial agents in vitro. Vol. 25. London: Springer-Verlag. pp. 159-171.
3. Hooper DC, Wolfson JS. 1985. The fluoroquinolones: Pharmacology, clinical uses, and toxicities in human. Antimicrob Agents Chemother 28:716-721.
4. Christ W. 1990. Central nervous system toxicity of quinolones: Human and animal findings. J Antimicrob Chemother 26:219-225.
5. Dimpfel W, Dalhoff A, von Keutz E. 1996. In vitro modulation of hippocampal pyramidal cell response by quinolones: Effects of HA 966 and gammahydroxybutyric acid. Antimicrob Agents Chemother 40:2573-2576.
6. Stahlmann R. 2002. Clinical toxicological aspects of fluoroquinolones. Toxicol Lett 127:269-277.
7. Forsgren A, Bredberg A, Pardee AB, Schlossman SF, Tedder TF. 1987. Effects of ciprofloxacin on eukaryotic pyrimidine nucleotide biosynthesis and cell growth. Antimicrob Agents Chemother 31:774-779.
8. Schuck G, Schurmann A, Schluter G. 1998. Determination of the excitatory potencies of fluroquinolones in the central nervous system by an in vitro model. Antimicrob Agents Chemother 42:1831-1836.
9. Oomori Y, Yasue T, Aoyama H, Hirai K, Suzue S, Yokota T. 1988. Effects of fleroxacin on HeLa cell functions and topoisomerase II. J Antimicrob Chemother 22:91-97.
10. Bredberg A, Brant M, Riesbeck K, Azou Y, Forsgren A. 1989. 4-Quinolone antibiotics: Positive genotoxic screening tests despite an apparent lack of mutational induction. Mutat Res 311:171-180.
11. Ball P. 2000. Quinolone generations: Natural history or natural selection? J Antimicrob Chemother 46:17-24.
12. Mandell L. 2000. Gemifloxacin: Survival of the fittest. J Antimicrob Chemother 46:33-37.
13. Cormican MG, Jones RN. 1997. Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone. Antimicrob Agents Chemother 41:204-211.
14. Johnson DM, Jones RN, Erwin ME. 1998. Pharmacodynamics in the evaluation of drug regimens. Diagn Microbiol Infect Dis 33:87-91.
15. Doyle E, Fowles SE, McDonnell DF, McCarthy R, White SA. 2000. Rapid determination of gemi-floxacin in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 746:191-198.
16. Allen A, Bygate E, Vousden M, Oliver S, Johnson M, Ward C, Cheon AJ, Choo YS. 2001. Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers. Antimicrob Agents Chemother 45:540-545.
17. Delon A, Bouquet S, Huguet F, Brunet V, Courtois P, Couet W. 1999. Pharmacokinetic-pharmacodynamic contributions to the convulsant activity of fluoroquinolones in rats. Antimicrob Agents Chemother 43:1511-1515.
18. Delon A, Huguet F, Courtois P, Vierfond JM, Bouquet S, Couet W. 1997. Pharmacokineticpharmacodynamic contributions to the convulsant activity of pefloxacin and NOR in rats. J Pharmacol Exp Ther 280:983-987.
19. Delon A, Levasseur LM, Giraudon M, Bouquet S, Coue W. 1999. Antagonistic interaction between the convulsant activities of pefloxacin and its main metabolite NOR in rats. Pharm Res 16:1894-1897.
20. De Sarro A, Ammendola D, Zappala M, Grasso S. 1995. Relationship between structure and convulsant properties of some b-lactam antibiotics following intracerebroventricular microinjection in rats. Antimicrob Agents Chemother 39:232-237.
21. Williams PD, Bennett DB, Comereski CR. 1988. Animal model for evaluating the convulsive liability of β-lactam antibiotics. Antimicrob Agents Chemother 32:758-760.
22. Day IP, Goudie J, Nishiki K, Williams PD. 1994. Correlation between in vitro and in vivo models of proconvulsive activity with the carbapenem antibiotics, biapenem, imipenem/cilastatin and meropenem. Toxicol Lett 76:239-243.
23. Patel JB, Giles RE. 1989. Meropenem: Evidence of lack of proconvulsive tendency in mice. J Antimicrob Chemother 24:307-309.
24. Marchand S, Pariat C, Bouquet S, Courtois P, Couet W. 2000. Pharmacokinetic-pharmacodynamic modelling of the convulsant interaction between norfloxacin and biphenyl acetic acid in rats. Br J Pharmacol 129:1609-1616.
25. Levasseur LM, Delon A, Greco WR, Faury P, Bouquet S, Couet W. 1998. Development of a new quantitative approach for the isobolographic assessment of the convulsant interaction between pefloxacin and theophylline in rats. Pharm Res 15:1069-1076.
26. Ramzan IM, Levy G. 1985. Kinetics of drug action in disease states. XIV. Effect of infusion rate on pentylenetetrazol concentrations in serum, brain and cerebrospinal fluid of rats at onset of convulsions. J Pharmacol Exp Ther 234:624-628.
27. Ramzan IM, Levy. G. 1986. Kinetics of drug action in disease states. XVI. Pharmacodynamics of theophylline induced seizures in rats. J Pharmacol Exp Ther 236:708-713.
28. Danhof M, Levy G. 1984. Kinetics of drug action in disease states. I. Effect of infusion rate on phenobarbital concentrations in serum, brain and cerebrospinal fluid of normal rats at onset of loss of righting reflex. J Pharmacol Exp Ther 229: 44-50.
29. De Sarro A, Ammendola D, De Sarro G. 1994. Effects of some quinolones on imipenem inducedseizures in DBA/2 mice. Gen Pharmacol 25:369-379.
30. De Sarro A, Imperatore C, Mastroeni P, De Sarro G. 1995. Comparative convulsant potencies of two carbapenem derivatives in C57 and DBA/2 mice. J Pharm Pharmacol 47:292-296.
31. De Sarro G, Nava BF, Calapai G, De Sarro A. 1997. Effects of some excitatory amino acid antagonists and drugs enhancing g-aminobutyric acid neuro-transmission on pefloxacin-induced seizures in DBA/2 mice. Antimicrob Agents Chemother 41: 427-434.
32. Cox EH, Kerbusch T, Van Der Graaf PH, Danhof M. 1998. Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: Correlation with the interaction at the Mu-opioid receptor. J Pharmacol Exp Ther 284:1095-1103.
33. Mandema JW, Tukker E, Danhof M. 1991. Pharmacokinetic-pharmacodynamic modelling of the EEG effects of midazolam in individual rats: Influence of rate and route of administration. Br J Pharmacol 102:663-668.
34. Akaike A. 1978. Probabilities for choosing a regression model. Ann Inst Math Stat 30:A9-A14.
35. Schwarz G. 1978. Estimating the dimension of a model. Ann Stat 6:461-464.
36. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. 1979. Simultaneous modelling of pharmacokinetics and pharmacodynamics: Application of d-tubocurarine. Clin Pharmacol Ther 25:358-371.
37. Della Paschoa OE, Mandema JW, Voskuyl RA, Danhof M. 1998. Pharmacokinetic-pharmacodynamic modeling of the anticonvulsant and electroencephalogram effects of phenytoin in rats. J Pharmacol Exp Ther 284:460-466.
38. Snedecor GW, Cochran WG. 1989. Statistical methods. 8th edition. Ames, IA: Iowa State University Press.
39. Zar JH. 1996. Biostatistical analysis. 3rd edition. Upper Saddle River, NJ: Prentice Hall.
40. Hammarlund-Udenaes M, Paalzow KK, Lange ECM. 1996. Drug equilibration across the blood-brain barrier-Pharmacokinetic considerations based on the microdialysis method. Pharm Res 14:128-134.
41. Welty DF, Schielke GG, Vartanian MG, Taylor CP. 1993. Gabapentin anticonvulsant action in rats: Disequilibrium with peak drug concentrations in plasma and brain microdialysate. Epilepsy Res 16: 175-181.
42. Jusko WJ, Ko HC. 1994. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 56:406-419.
43. Hori S, Shimada J, Saito A. 1989. Comparison of the inhibitory effects of new quinolones on gammaaminobutyric-acid receptor binding in the presence of anti-inflammatory drugs. Rev Infect Dis 11:s1397-s1398.
44. Bouw MR, Xie R, Tumblad K, Hammarlund-Udenaes M. 2001. Blood-brain barrier transport and brain distribution of morphin-6-glucuronide in relation to the antinociceptive effect in rats. Pharmacokinetic/pharmacodynamic modeling. Br J Pharmacol 134:1796-1804.
45. Dayneka NL, Garg V, Jusko WJ. 1993. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21:457-478.
46. Ramji JV, Austin NE, Boyle GW, Chalker MH, Duncan G, Fairless AJ, Hollis FJ, Mcdonnell DF, Musick TJ, Shardlow PC. 2001. The disposition of gemifloxacin, a new fluoroquinolone antibiotic, in rats and dogs. Drug Metab Dispos 29:435-442.
47. Domagala JM. 1994. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J Antimicrob Chemother 33:685-706.
48. Otman WR, Nightingale CH. 1989. Metabolism and fluoroquinolones. Am J Med 87:37s-42s.
49. Sorgel F. 1989. Metabolism of gyrase inhibitors. Rev Infect Dis 11:s1119-s1129.